{
    "organizations": [],
    "uuid": "6eeecf71d2e59b21d37a8745f55a7f2d12236807",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/idUSFWN1RG0F2",
    "ord_in_thread": 0,
    "title": "REFILE-BRIEF-Rigel Announces Topline Data From Phase 2 Study Of Fostamatinib",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "(Refiles to correct formatting of bullets)\nApril 3 (Reuters) - Rigel Pharmaceuticals Inc:\n* RIGEL ANNOUNCES TOPLINE DATA FROM PROOF-OF-CONCEPT PHASE 2 STUDY OF FOSTAMATINIB IN IGA NEPHROPATHY\n* TRIAL DID NOT ACHIEVE STATISTICAL SIGNIFICANCE FOR ITS PRIMARY ENDPOINT\n* ‍FOSTAMATINIB WAS WELL TOLERATED WITH MOSTLY MILD TO MODERATE ADVERSE EVENTS​\n* FURTHER ANALYSIS OF THE TREATMENT, INCLUDING HISTOLOGY, ARE EXPECTED LATER IN YEAR\n* ‍THERE WERE NO NEW SAFETY SIGNALS COMPARED TO FOSTAMATINIB’S SAFETY DATABASE ACROSS ALL INDICATIONS​\n* PATIENTS WITH GREATER THAN 1 GRAM/DAY OF PROTEINURIA HAVE AN INCREASED RISK OF DISEASE PROGRESSION AND REPRESENT AN UNMET MEDICAL NEED\n* ‍RIGEL PLANS TO SEEK A PHARMACEUTICAL PARTNER TO COLLABORATE IN CONDUCT OF FOLLOW-ON CLINICAL STUDIES IN IGAN​\n* PHARMACEUTICAL​ PARTNER WOULD TAKE RESPONSIBILITY FOR SUBSEQUENT COMMERCIALIZATION OF FOSTAMATINIB IF IN AN EX-U.S. TERRITORY Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-03T19:11:00.000+03:00",
    "crawled": "2018-04-04T12:15:51.046+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "refiles",
        "correct",
        "formatting",
        "bullet",
        "april",
        "reuters",
        "rigel",
        "pharmaceutical",
        "inc",
        "rigel",
        "announces",
        "topline",
        "data",
        "phase",
        "study",
        "fostamatinib",
        "iga",
        "nephropathy",
        "trial",
        "achieve",
        "statistical",
        "significance",
        "primary",
        "endpoint",
        "well",
        "tolerated",
        "mostly",
        "mild",
        "moderate",
        "adverse",
        "analysis",
        "treatment",
        "including",
        "histology",
        "expected",
        "later",
        "year",
        "new",
        "safety",
        "signal",
        "compared",
        "fostamatinib",
        "safety",
        "database",
        "across",
        "patient",
        "greater",
        "proteinuria",
        "increased",
        "risk",
        "disease",
        "progression",
        "represent",
        "unmet",
        "medical",
        "need",
        "plan",
        "seek",
        "pharmaceutical",
        "partner",
        "collaborate",
        "conduct",
        "clinical",
        "study",
        "partner",
        "would",
        "take",
        "responsibility",
        "subsequent",
        "commercialization",
        "fostamatinib",
        "territory",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}